Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating Olo Inc. and its leadership for potential breaches of fiduciary duties related to the company's pending acquisition by Thoma Bravo at a price of $10.25 per share [1][4]. Group 1: Company Overview - Olo Inc. operates as an open SaaS platform for restaurants, facilitating digital commerce operations including ordering, delivery, engagement, and payments [3]. - The company's stock is divided into Class A and Class B shares, with Class B shares having ten votes per share compared to one vote for Class A shares [3]. - As of December 31, 2024, directors and executive officers collectively owned approximately 82% of the voting power of Olo's outstanding capital stock [3]. Group 2: Acquisition Details - On July 3, 2025, Olo announced a definitive agreement to be acquired by Thoma Bravo in an all-cash transaction valued at approximately $2 billion in equity [3]. - Shareholders will receive $10.25 per share, representing a 65% premium over Olo's unaffected share price of $6.20 as of April 30, 2025 [3]. Group 3: Legal Investigation - The investigation by BFA Law focuses on whether Olo's board, executive officers, and CEO Noah H. Glass breached their fiduciary duties in connection with the merger [4]. - Current shareholders of Olo are encouraged to seek additional information regarding their legal options [2][5].

Group 1 - Omnicom's acquisition of Interpublic has received approval from the Australia Competition and Consumer Commission (ACCC), marking the 14th out of 18 necessary antitrust approvals for the transaction [1] - The merger is expected to transform the marketing industry, leading to growth for employees, improved client outcomes, and significant long-term value for shareholders [2] - Omnicom is a leading provider of data-inspired marketing solutions, serving over 5,000 clients in more than 70 countries [3] Group 2 - Interpublic is a creatively driven marketing solutions provider, home to many well-known global brands and communications specialists [4]

Core Viewpoint - Aptorum Group Limited has announced a definitive agreement for an all-stock merger with DiamiR Biosciences, which will become a wholly-owned subsidiary of Aptorum, retaining its name and continuing to be listed on the Nasdaq Stock Market after the merger [1][4]. Company Overview - Aptorum Group is a clinical stage biopharmaceutical company focused on addressing unmet medical needs in oncology and infectious diseases [8]. - DiamiR Biosciences specializes in developing proprietary blood-based tests for brain health and other diseases, operating a CLIA licensed, CAP accredited clinical laboratory [1][9]. Merger Details - The merger will involve Aptorum re-domiciling to Delaware and acquiring all outstanding capital stock of DiamiR in exchange for shares representing approximately 70% of the combined company's common stock, with current Aptorum equity holders retaining 30% [3][4]. - The merger agreement has been approved by the boards of both companies and is subject to stockholder approval and customary closing conditions, with an expected closing in the fourth quarter of 2025 [4][6]. Leadership and Structure - Post-merger, the combined company will be headquartered in Princeton, New Jersey, with Ian Huen as CEO, Dr. Alidad Mireskandari as President and COO, and Gary Anthony as CFO [5]. - The board of directors will consist of five members, with three designated by Aptorum and two by DiamiR [5]. Strategic Goals - The merger aims to create a global life sciences company capable of generating revenue through biopharma services and offering biomarker panels for complex-biology indications, particularly in aging-related diseases and brain health [2][3]. - DiamiR's expertise in assay development and commercialization is expected to enhance the combined company's capabilities in non-invasive blood-based testing [2].

Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating Olo Inc. and its leadership for potential breaches of fiduciary duties related to the company's pending acquisition by Thoma Bravo for $10.25 per share, valuing Olo at approximately $2 billion in equity [1][3][4]. Company Overview - Olo Inc. operates an open SaaS platform for restaurants, facilitating digital commerce operations including ordering, delivery, engagement, and payments [3]. - The company's stock is divided into Class A and Class B shares, with Class B shares having ten votes per share compared to one vote for Class A shares. As of December 31, 2024, directors and executive officers collectively owned approximately 82% of the voting power of Olo's outstanding capital stock [3]. Acquisition Details - On July 3, 2025, Olo announced a definitive agreement to be acquired by Thoma Bravo in an all-cash transaction [3]. - The acquisition price of $10.25 per share represents a 65% premium over Olo's unaffected share price of $6.20 as of April 30, 2025, indicating a significant increase in shareholder value [3].

Core Viewpoint - DallasNews Corporation is set to be acquired by Hearst, enhancing its legacy of independent journalism with Hearst's resources and industry reputation [1][3]. Company Overview - DallasNews Corporation is the holding company for The Dallas Morning News and Medium Giant, known for its strong journalistic reputation and community ties [7]. - The Dallas Morning News has won nine Pulitzer Prizes, highlighting its commitment to quality journalism [7]. - Medium Giant is an integrated creative marketing agency that has received multiple industry awards, including the AAF Addy and the AMA DFW Annual Marketer of the Year [8]. Acquisition Details - Shareholders of DallasNews will receive $14.00 in cash per share, representing a 219% premium over the closing price of $4.39 on July 9, 2025 [3]. - The acquisition has been unanimously approved by the Boards of Directors of both companies and is expected to close in the third or early fourth quarter of 2025 [3][4]. Strategic Implications - Upon completion, The Dallas Morning News will join Hearst Newspapers, which publishes 28 dailies and 50 weeklies across the U.S. [4]. - Hearst plans to invest in The Dallas Morning News' digital strategy and journalism, aiming to expand its audience reach [5]. - The acquisition aligns with Hearst's strategy of supporting trusted local media brands in growth markets [5]. Leadership Statements - Hearst Newspapers' president emphasized the commitment to support The Dallas Morning News through investments in digital strategy and journalism [5]. - The CEO of DallasNews highlighted the shared values with Hearst and the importance of their resources for the future of The Dallas Morning News [5]. Transition to Private Company - Following the acquisition, DallasNews Corporation will become a private entity, and its shares will no longer be traded on Nasdaq [5].

Core Viewpoint - CARGO Therapeutics has entered into a definitive merger agreement with Concentra Biosciences, where Concentra will acquire CARGO for $4.379 per share in cash, along with contingent value rights [1][2] Group 1: Merger Agreement Details - The acquisition price includes $4.379 in cash per share of CARGO common stock and one non-transferable contingent value right (CVR) [1] - The CVR entitles holders to receive 100% of CARGO's net cash exceeding $217.5 million and 80% of net proceeds from certain product candidates sold within two years post-closing [1] - The CARGO board unanimously approved the merger, deeming it in the best interests of all stockholders [2] Group 2: Tender Offer Process - Concentra will initiate a tender offer by July 21, 2025, to acquire all outstanding shares of CARGO common stock [3] - The closing of the offer is contingent upon the tender of a majority of outstanding shares and the availability of at least $217.5 million in cash at closing [3] - Approximately 17.4% of CARGO common stockholders have signed agreements to support the merger and tender their shares [3] Group 3: Advisors - TD Cowen is serving as the exclusive financial advisor to CARGO, while Latham & Watkins LLP is providing legal counsel to CARGO [4] - Gibson, Dunn & Crutcher LLP is acting as legal counsel to Concentra [4] Group 4: Company Background - CARGO Therapeutics is a biotechnology company focused on developing CAR T-cell therapies for cancer patients [5]

Core Viewpoint - Kaskela Law LLC has initiated an investigation into the fairness of the proposed buyout of NV5 Global, Inc. to assess whether the buyout price adequately reflects the company's value [1][3]. Group 1: Buyout Details - NV5 announced an agreement to be acquired by Acuren Corporation at a price of $23.00 per share, which includes $10.00 in cash and $13.00 in Acuren's stock [2]. - Following the transaction's completion, NV5's shareholders will be cashed out, and the company's shares will cease to be publicly traded [2]. Group 2: Investigation Focus - The investigation aims to determine if NV5's investors are receiving sufficient financial consideration for their shares and whether the company's officers or directors violated fiduciary duties or securities laws in agreeing to the buyout price [3]. - At the time of the announcement, at least one stock analyst had a price target of $28.00 per share for NV5, indicating a potential undervaluation in the proposed buyout [3].

Brazil’s presidential election in 2026 will be key to unlocking more action in the merger-and-acquisition market, some of the nation’s top investment bankers say https://t.co/fTn7IZoyEc ...

Core Viewpoint - The merger between Channel Therapeutics Corporation and LNHC, Inc. has been completed, leading to the formation of Pelthos Therapeutics Inc., which will focus on launching ZELSUVMI™ for treating molluscum contagiosum infections starting July 2025 [1][2]. Company Overview - Pelthos Therapeutics Inc. is a biopharmaceutical company dedicated to commercializing innovative therapeutic products for high unmet patient needs [1][7]. - The company will trade on the NYSE American exchange under the ticker symbol "PTHS" beginning July 2, 2025 [1]. Merger Details - The merger involved CHRO Merger Sub Inc., a subsidiary of Channel Therapeutics, merging with LNHC, Inc., a subsidiary of Ligand Pharmaceuticals, with LNHC continuing as a subsidiary of Channel [1]. - The merger is seen as a significant milestone for Pelthos, facilitating the launch of ZELSUVMI™ and creating shareholder value [2][5]. Financial Aspects - Concurrent with the merger, Pelthos closed a $50.1 million equity private placement from strategic investors, which includes the cancellation of approximately $18.8 million in bridge capital previously advanced to support ZELSUVMI™'s commercial launch [3][5]. - The private placement involves investments in Series A Convertible Preferred Stock and common stock [3]. Product Information - ZELSUVMI™ (berdazimer) is a topical gel approved for treating molluscum contagiosum in adults and pediatric patients aged one year and older [4][6]. - It is the first and only prescription medication for this condition that can be administered at home, making it a novel treatment option [4][6]. - The product was developed using Pelthos' proprietary nitric oxide-based technology platform, NITRICIL™ [6]. Market Opportunity - Molluscum contagiosum is a common skin infection affecting an estimated 16.7 million people in the United States, indicating a significant market opportunity for ZELSUVMI™ [4].

Financial Performance & Ratios - UBSI achieved a net income of $373 million and diluted earnings per share of $2.75 in 2024[11] - The company's Return on Average Assets was 1.26%, Return on Average Equity was 7.61%, and Return on Average Tangible Equity was 12.43% in 2024[11] - Net Interest Margin (FTE) remained solid at 3.49%[11] - The efficiency ratio was 52.67%[11] Balance Sheet & Loan Portfolio - Total assets reached $30 billion, and pro forma total assets with Piedmont were $32 billion as of December 31, 2024[6] - Gross loans totaled $22 billion, and pro forma gross loans with Piedmont were $24 billion as of December 31, 2024[6] - Total deposits amounted to $24 billion, and pro forma total deposits with Piedmont were $26 billion as of December 31, 2024[6] - Non-Performing Assets (NPAs) increased to $73727000, representing 0.25% of total assets as of December 31, 2024[28] Piedmont Merger & Outlook - UBSI completed the merger with Piedmont Bancorp, Inc on January 10, 2025[8] - Net interest income (non-FTE) is expected to be in the range of $102 billion to $105 billion for 2025, including ~$20 million from Piedmont acquisition[54]